| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Viatris Inc (NASDAQ: VTRS)
VTRS Technical Analysis
5
| As on 9th Jun 2023 VTRS STOCK Price closed @ 9.38 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 11.23 & Strong Sell for SHORT-TERM with Stoploss of 14.06 we also expect STOCK to react on Following IMPORTANT LEVELS. |
VTRSSTOCK Price
| Open | 9.46 | Change | Price | % |
| High | 9.49 | 1 Day | -0.14 | -1.47 |
| Low | 9.34 | 1 Week | 0.27 | 2.96 |
| Close | 9.38 | 1 Month | 0.20 | 2.18 |
| Volume | 6546404 | 1 Year | -3.65 | -28.01 |
| 52 Week High 15.40 | 52 Week Low 8.52 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| VTRS Daily Charts |
VTRS Intraday Charts |
Whats New @ Bazaartrend |
VTRS Free Analysis |
|
|
VTRS Important Levels Intraday
| RESISTANCE | 9.67 |
| RESISTANCE | 9.58 |
| RESISTANCE | 9.52 |
| RESISTANCE | 9.46 |
| SUPPORT | 9.30 |
| SUPPORT | 9.24 |
| SUPPORT | 9.18 |
| SUPPORT | 9.09 |
VTRS Forecast May 2024
| 4th UP Forecast | 12.54 |
| 3rd UP Forecast | 11.53 |
| 2nd UP Forecast | 10.9 |
| 1st UP Forecast | 10.27 |
| 1st DOWN Forecast | 8.49 |
| 2nd DOWN Forecast | 7.86 |
| 3rd DOWN Forecast | 7.23 |
| 4th DOWN Forecast | 6.22 |
VTRS Weekly Forecast
| 4th UP Forecast | 10.90 |
| 3rd UP Forecast | 10.41 |
| 2nd UP Forecast | 10.11 |
| 1st UP Forecast | 9.81 |
| 1st DOWN Forecast | 8.95 |
| 2nd DOWN Forecast | 8.65 |
| 3rd DOWN Forecast | 8.35 |
| 4th DOWN Forecast | 7.86 |
VTRS Forecast2024
| 4th UP Forecast | 23.2 |
| 3rd UP Forecast | 18.77 |
| 2nd UP Forecast | 16.03 |
| 1st UP Forecast | 13.29 |
| 1st DOWN Forecast | 5.47 |
| 2nd DOWN Forecast | 2.73 |
| 3rd DOWN Forecast | -0.01 |
| 4th DOWN Forecast | -4.44 |
Viatris Inc ( NASDAQ USA Symbol : VTRS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
VTRS Business Profile
Viatris Inc., a healthcare company, develops, licenses, manufactures, markets, and distributes brand and generic drugs, complex generics, biosimilars, and active pharmaceutical ingredients (APIs) worldwide. The company operates through Developed Markets, Greater China, JANZ, and Emerging Markets segments. It offers drugs in various therapeutic areas, including infectious diseases and non-communicable diseases; HIV/AIDS; and oncology, immunology, endocrinology, ophthalmology, and dermatology, as well as antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas. The company provides medicines, such as Wixela, Inhub, ADVAIR DISKUS, glatiramer acetate injection, Copaxone, and over the counter products in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions; and support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. The company sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, and EpiPen auto-injector; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; Trastuzumab injection; and Celebrex and anti-retrovirals names, as well as offers biosimilars franchises, including Fulphila, Ogivri, and Hulio. Viatris Inc. has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Canonsburg, Pennsylvania. Address: 1000 Mylan Boulevard, Canonsburg, PA, United States, 15317
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service